ACEi to ARNi: “The Switch” An Evidence Based Review
Main Article Content
Downloads
Article Details
Copyright (c) 2020 Hassan Y, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Mentzer G, Hsich EM (2019) Heart Failure with Reduced Ejection Fraction in Women. Heart Fail Clin 15: 19-27. Link: https://bit.ly/2HJBlzs
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, et al. (2014) Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 371: 993-1004. Link: https://bit.ly/31VwSkt
Yancy CW, Jessup CM, Bozkurt B, Butler J, Casey DE, et al. (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136: e137-e161. Link: https://bit.ly/37V6ZVA
Consensus Trial Study Group (1987) Effects of Enalapril on Mortality in Severe Congestive Heart Failure. N Engl J Med 316: 1429-1435. Link: https://bit.ly/3jGTTO7
Kramer BL, Massie BM, Topic N (1983) Controlled Trial of Captopril in Chronic Heart Failure: A Rest and Exercise Hemodynamic Study. Circulation 67: 807-816. Link: https://bit.ly/37UPsgo
SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN, (1991) Effect of Enalapril on Survival in Patients with Reduced Left Ejection Fraction And Congestive Heart Failure. NEJM 35: 293-302. Link: https://bit.ly/3kHsCfE
Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273: 1450-1456. Link: https://bit.ly/31Vz4Z6
Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, et al. (2017) Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ Clin Res 356: j4. Link: https://bit.ly/37RHLr1
(1998) Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. 97: 2202. Link: https://bit.ly/2TEb20g
Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA (2004) Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes Diabetes Care 27: 1330-1334. Link: https://bit.ly/31UfMTX
Pitt B, Segal R, Martinez FA, Cowley AJ, Meurers G, et al. (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747-752. Link: https://bit.ly/35LlGYG
Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, et al. (2004) Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141: 693-704. Link: https://bit.ly/2GaKxfE
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al. (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. NEJM 347: 161-167. Link: https://bit.ly/34FxDQl
Shatsky M (2006) Nesiritide (Natrecor) for Acute Decompensated Heart Failure. Am Fam Physician 73: 687-688. Link: https://bit.ly/3mynsmG
Boomama F, Van der Meiracker AH (2001) Plasma A‐ and B‐type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 51 :442-449. Link: https://bit.ly/3eg5Itl
Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, et al. (2012) Novel protein therapeutics for systolic heart failure: chronic subcutaneous B‐type natriuretic peptide. J Am Coll Cardiol 60: 2305-2312. Link: https://bit.ly/2HKe7ZR
Cleland JG, Swedberg K (1998) Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet (London, England) 351: 1657-1658. Link: https://bit.ly/3kIAHR5
Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, et al. (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106: 920-926. Link: https://bit.ly/3e8vHmt
Diez J (2017) Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail 19: 167-176. Link: https://bit.ly/3jKN91n
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, et al. (2019) Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure List of authors. N Engl J Med 380: 539-548. Link: https://bit.ly/3jFu4xG
Nakamura M, Arakawa N, Yoshida H, Makita S, Niinuma H, et al. (1998) Vasodilatory effects of B‐type natriuretic peptide are impaired in patients with chronic heart failure. Am Heart J 135: 414-420. Link: https://bit.ly/35Qn8sE
Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, et al. (1986) Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 78: 1362-1374. Link: https://bit.ly/2Jk0XUh
Eiskjaer H, Bagger JP, Danielsen H, Jensen JD, Jespersen B, et al. (1991) Attenuated renal excretory response to atrial natriuretic peptide in congestive heart failure in man. Int J Cardiol 33: 61-74. Link: https://bit.ly/37Ul1Xq
Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, et al. (2007) Prediction of Mode of Death in Heart Failure The Seattle Heart Failure. Circulation 116: 392-398. Link: https://bit.ly/2HPXvjR
Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y, Yamaoka O, et al. (1993) Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 87: 70-75. Link: https://bit.ly/34CiFdQ
Ziaeian B, Fonarow GC (2016) Epidemiology and aetiology of heart failure. Nat Rev Cardiol 13: 368-378. Link: https://bit.ly/3e6OMFI
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 329: 1456-1462. Link: https://bit.ly/3kBOqJz
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863. Link: https://bit.ly/3oFKH08
Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, et al. (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364. Link: https://bit.ly/3eh5pyA
Maschio G, Alberti D, Janin G, et al, and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med . 1996; 334: 939–94
Sarafidis PA, Khosla N, Bakris GL (2007) Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 49: 12-26. Link: https://bit.ly/34He0qQ
Chiurchiu, C, Remuzzi G, Ruggenenti P (2005) Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses. 16: S58-S63. Link: https://bit.ly/37SgpkL
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, et al. (2019) Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 381: 1609-1620. Link: https://bit.ly/3jHUyi0
Solomon SD, McMurray JJV, Claggett BL, Packer M, Zile M, et al. (2019) Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation 141: 352-361. Link: https://bit.ly/2JnF1Yx
Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, et al. (2020) Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail 8: 789-799. Link: https://bit.ly/2JkUkB6
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, (2003) Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular dysfunction or Both, Valsartan in Acute Myocardial Infarction Trial Investigators. *N Engl J Med 349: 1893-1906. Link: https://bit.ly/3mBooqA
Silver MA, Maisel A, Yancy CW, McCullough PA¸ Burnett JC, et al. (2004) BNP Consensus Panel 2004: A Clinical Approach for the Diagnostic, Prognostic, Screening, Treatment Monitoring, and therapeutic Roles of Natriuretic Peptides in Cardiovascular Diseases. Congest Heart Fail 10: 1-30. Link: https://bit.ly/31UWyxy